Centaur Pharma launches WOXHeal for treatment of diabetic foot ulcer

New Delhi: Centaur Pharmaceuticals on Tuesday announced the launch of a New Chemical Entity (NCE) – WOXheal – for the first time in the world.

A globally patented product, WOXheal topical solution, contains the NCE, Diperoxochloric acid, also called as DPOCL. WOXheal has a dual mechanism of action, i.e. it has functional antibacterial action against Gram positive and Gram negative bacteria and it also promotes growth of fibroblast cells, thereby yielding complete wound closure, said the company.

In a release, the company said randomized clinical trials conducted across India in over 15 clinical trial centres on WOXheal elucidated that over 90% patients with non-healing diabetic foot ulcer showed reduction in the size of the ulcer, and 75% out of these patients achieved complete healing within 6-8 weeks without any safety issue.

The data and outcomes of the trial were submitted to the Indian Regulatory Authority and a manufacturing and marketing approval was granted to Centaur Pharmaceuticals for WOXheal.

“We, at Centaur Pharmaceuticals were deeply concerned with the alarming rate of foot amputations in India, and wanted to discover a drug to prevent it. Fifteen years ago, we collaborated with CytoTools AG, Germany, who had this promising molecule for the treatment of Diabetic foot ulcer. We are very happy to offer this ray of hope to people with Diabetic foot ulcer in India,” said S. D. Sawant, CMD, Centaur Pharmaceuticals.

WOXheal will be readily available in the entire country by the end of the month.

"WOXheal has completed Phase III clinical trials in India and demonstrated rapid and effective wound healing in patients with Diabetic foot ulcers, a condition that is notoriously difficult to treat," said Dr. Mark-Andre Freyberg, the co-innovator of WOXheal and the Chief Executive Officer of CytoTools AG, Germany.